TITLE

OTHER NEWS TO NOTE

PUB. DATE
February 2010
SOURCE
BioWorld Today;2/2/2010, Vol. 21 Issue 21, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on the biotechnology industry including an exclusive worldwide licensing deal signed by Abbott with Pierre Fabre SA, the execution of a license agreement by Achillion Pharmaceuticals Inc. for elvucitabine, and the research agreements signed by Asuragen Inc. with several organizations, which include the University of Pittsburgh Medical Center.
ACCESSION #
47906379

 

Related Articles

  • PIERRE FABRE LICENSES PHARMAGENESIS ANTI-CANCER HERBAL DRUG.  // Worldwide Biotech;May2003, Vol. 15 Issue 5, p5 

    Reports that research and development company, Pharmagenesis Inc. has signed an agreement with Pierre Fabre Medicament to license PG490-88Na, a patented derivative of a compound from a plant widely used in Chinese medicine.

  • BMS Licenses Phase III Cancer Drug.  // Chemical Market Reporter;4/26/2004, Vol. 265 Issue 17, p3 

    Reports on the move of Bristol-Myers Squibb (BMS) Co. in seeking to strengthen its oncology franchise by licensing a late-phase cancer drug from Pierre Fabre Médicament SA in Paris, France. Success of BMS in taking an exclusive license to market Javlor vinflunine; Presentation of the phase...

  • Hot product.  // Drug Store News;6/17/96, Vol. 18 Issue 9, p69 

    Reports on Azusa, California-based Pierre Fabre's strength in the concealer category due to the strong sales of its Physicians Formula concealer products for the 52 weeks ended December 1995. Market share; Category growth; Product launches focusing on color correcting skin discoloration...

  • Back to nature.  // Life Science Today;Feb2001, Vol. 2 Issue 1, p6 

    Reports on the research and development venture launched by French drugmaker Pierre Fabre which focuses on natural substances. Research body that will help Pierre on its research; Sources of the substances that will be developed by the company.

  • Pierre Fabre. WEIL, JENNIFER // WWD: Women's Wear Daily;7/22/2013, Vol. 206 Issue 13, p12 

    The article presents an obituary for Pierre Fabre, founder of founder and president of pharmaceutical and cosmetics business, Laboratoires Pierre Fabre.

  • Value drivers in licensing deals. Arnold, Katie; Coia, Anthony; Saywell, Scott; Smith, Ty; Minick, Scott; Löffler, Alicia // Nature Biotechnology;Nov2002, Vol. 20 Issue 11, p1085 

    Determines the appropriate gauge on how the value of licensing deals in commercial biotechnology is identified, enhanced and captured. Three quantitative methods used to analyze biotechnology products; Value of product deals between biotechnology and pharmaceutical companies; Impact of the type...

  • Durascreen gets new marketing approach.  // Drug Store News;11/4/96, Vol. 18 Issue 18, p43 

    Reports that Pierre Fabre Dermo-Cosmetique is embarking on an aggressive marketing and educational program for the DuraScreen sun care brand. Acquisition of the brand; Marketing strategies.

  • Pierre Fabre introduces French A-Derma line to U.S. Malbin, Peter // Drug Store News;9/8/97, Vol. 19 Issue 14, p49 

    Reports on Pierre Fabre's plan to introduce its A-Derma skin care line in the United States. Price range; Product testing conducted in October 1997.

  • Pharma: Other News To Note.  // BioWorld Today;1/18/2013, Vol. 24 Issue 13, p7 

    The article reports that Castres, France-based Laboratoires Pierre Fabre Dermatologie, a subsidiary of Laboratoires Pierre Fabre and Maruho Co. Ltd. of Osaka, Japan, has entered a licensing deal to develop and market an oral formulation of a pediatric beta-blocker in Japan.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics